DS-107
- Generic Name
- DS-107
Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- DS Biopharma
- Target Recruit Count
- 219
- Registration Number
- NCT03817190
- Locations
- 🇺🇸
DS Investigational Site 527, Doral, Florida, United States
🇺🇸DS Investigational Site 521, Medford, Oregon, United States
🇦🇹DS Investigational Site 101, Graz, Austria
Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- DS Biopharma
- Target Recruit Count
- 327
- Registration Number
- NCT02925793
- Locations
- 🇿🇦
DS Biopharma Site, Cape Town, South Africa
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- DS Biopharma
- Target Recruit Count
- 321
- Registration Number
- NCT02864498
- Locations
- 🇿🇦
DS Biopharma Site, Cape Town, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath